Sage Journals: Discover world-class research

Abstract

This paper focuses on the most common state policy responses to the opioid crisis, dividing them into six broad categories. Within each category we highlight the rationale behind the group of policies within it, discuss the details and support for individual policies, and explore the research base behind them. The objective is to better understand the most prevalent state responses to the opioid crisis.

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention, “Drug Overdose Death Data,” available at <https://www.cdc.gov/drugover-dose/data/statedeaths.html> (last visited Jan. 21, 2018).

See, e.g.,

Murphy

et al ., Finding Solutions to the Prescription Opioid and Heroin Crisis: A Road Map for States, National Governor’s Association, available at <https://www.nga.org/files/live/sites/NGA/files/pdf/2016/1607NGAOpioidRoadMap.pdf> (last visited Jan. 21, 2018).

Id .

Blackman

, Preventing Opioid Misuse: Legislative Trends and Predictions, National Conference of State Legislatures, available at <http://www.ncsl.org/blog/2017/01/31/preventing-opioid-misuse-legislative-trends-and-predictions.aspx> (last visited Jan. 21, 2018).

Penm

et al ., “Strategies and Policies to Address the Opioid Epidemic: A Case Study of Ohio,” Journal of the American Pharmacists Association 57, no. 2 (2017): 148-153, available at <https://www.sciencedirect.com/science/article/pii/S1544319117300018> (last visited May 3, 2018).

Prescription Drug Monitoring Program Training and Technical Assistance Center, available at <http://www.pdmpassist.org> (last visited Jan. 21, 2018).

Vestal

, With Arkansas, Half the States Now Limit Pain-killer Prescriptions, Governing, available at <http://www.governing.com/topics/health-human-services/tns-arkansas-opioid-prescription-drugs.html> (last visited January 21, 2018).

Hill

et al ., “Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures,” Annals of Surgery 265, no. 4 (2017): 709–714, at 710, available at <https://insights.ovid.com/pubmed?pmid=27631771> (last visited May 3, 2018).

Scutti and

Kounang , “CVS Will Limit Opioid Prescriptions to 7 Days,” CNN, available at <https://www.cnn.com/2017/09/22/health/cvs-prescription-restrictions-opioids-bn/index.html> (last visited Jan. 21, 2018).

10.

Anuj

Shah

et al ., “Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use – United States, 2006-2015,” Morbidity and Mortality Weekly Report 66, no. 10 (2017): 265-269, at 267, available at https://www.cdc.gov/mmwr/volumes/66/wr/mm6610a1.htm (last visited January 21, 2018).

11.

Id .

12.

Vestal

, “In States, Some Resistance to New Opioid Limits,” The Pew Charitable Trusts, available at <http://www.pewtrusts.org/en/research-and-analysis/blogs/state-line/2016/06/28/in-states-some-resistance-to-new-opioid-limits> (last visited January 21, 2018). Also see N. Guevre-mont, M. Barnes, and C. E. Haupt, “Physician Autonomy and the Opioid Crisis,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 203-219.

13.

Prescription Drug Monitoring Program Training and Technical Assistance Center, “Prescription Drug Monitoring, Frequently Asked Questions (FAQ),” Prescription Drug Monitoring Program Training and Technical Assistance Center, available at <http://www.pdmpassist.org/content/prescription-drug-monitoring-frequently-asked-questions-faq> (last visited January 21, 2018).

14.

Suntrup and

Liss , “Missouri’s Version of Long-Awaited Prescription Monitoring Program is up and Running,” St. Louis Post-Dispatch, available at <www.stltoday.com/news/local/govt-and-politics/missouri-s-version-of-long-awaited-prescription-monitoring-program-is/article_082eaa5c-a898-5510-9158-557a2bef144c.html> (Last visited February 24, 2018).

15.

Prescription Drug Monitoring Program Training and Technical Assistance Center, supra note 6.

16.

Finklea

et al ., “Prescription Drug Monitoring Programs,” Congressional Research Service (March 24, 2014), available at <https://fas.org/sgp/crs/misc/R42593.pdf> (last visited January 21, 2018).

17.

Bao

et al ., “Prescription Drug Monitoring Programs Are Associated With Sustained Reductions in Opioid Prescribing By Physicians,” Health Affairs (Milwood) 35, no. 6 (2017): 1045-1051, at 1045, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336205> (last visited January 21, 2018); C. Griggs et al., “Prescription Drug Monitoring Programs: Examining Limitations and Future Approaches,” The Western Journal of Emergency Medicine 16, no. 1 (2015): 67-70, at 67, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307729> (last visited May 4, 2018).

18.

Finley

et al ., “Evaluating the Impact of Prescription Drug Monitoring Program Implementation: A Scoping Review,” BMC Health Services Research 17, no. 420 (2017): 420-427, at 423, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477729> (last visited May 4, 2018).

19.

Prescription Drug Monitoring Program Training and Technical Assistance Center, “PDMP Mandatory Enrollment of Prescribers and Dispensers,” available at <http://www.pdmpassist.org/pdf/Mandatory_Enrollment_5.pdf> (last visited January 21, 2018).

20.

Prescription Drug Monitoring Program Training and Technical Assistance Center, “PDMP Mandatory Query by Prescribers and Dispensers,” available at <http://pdmpassist.org/pdf/Mandatory_Query_6.pdf> (last visited January 21, 2018). Also see I. Ayres and A. Jalal, “The Impact of Prescription Drug Monitoring Programs on U.S. Opioid Prescriptions,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 387-403.

21.

Wen

et al ., “States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees,” Health Affairs (Milwood) 36 (2017): 733-741, at 733, available at <https://www.ncbi.nlm.nih.gov/pubmed/28373340> (last visited January 21, 2018); also see Ayers, supra note 20.

22.

C. S.

Davis and

Carr , “Physician Continuing Education to Reduce Opioid Misuse, Abuse, and Overdose: Many Opportunities, Few Requirements,” Drug and Alcohol Dependence 163 (2016): 100-107, at 100-101, available at <http://www.sciencedirect.com/science/article/pii/S0376871616300278> (last visited January 21, 2018).

23.

Id .

24.

Id .

25.

Marinopoulos

et al ., “Effectiveness of Continuing Medical Education,” Evidence Report/Technology Assessment 149 (2007): 1-69, available at <https://www.ncbi.nlm.nih.gov/pubmed/17764217> (last visited January 21, 2018).

26.

Alford

et al ., “SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program,” Pain Medicine 17, no. 1 (2016): 52-63, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718419> (last visited May 4, 2018).

27.

C.L.

Barry

, “Understanding Americans’ Views on Opioid Pain Reliever Abuse,” Addiction 111, no. 1 (2016): 85-93, at 89-90

28.

Livingston

, “The Effectiveness of Interventions for Reducing Stigma Related to Substance Use Disorders: A Systematic Review,” Addiction 107, no. 1 (2012): 39-50, at 45-46, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272222/> (last visited May 4, 2018).

29.

“Real Stories From Montana,”

Resolve Montana, available at <http://resolvemontana.org/> (last visited January 21, 2018); “Campaign Materials,” Zero Addiction, available at <http://www.zeroaddiction.org/campaign-materials> (last visited Jan. 21, 2018).

30.

As determined by state-by-state online searches.

31.

“Trump Administration Awards Grants to States to Combat Opioid Crisis,”

U.S. Department of Health and Human Services, available at <https://www.hhs.gov/about/news/2017/04/19/trump-administration-awards-grants-states-combat-opioid-crisis.html> (last visited January 21, 2018).

32.

Allara

et al ., “Are Mass-Media Campaigns Effective in Preventing Drug Use? A Cochrane Systematic Review and Meta-Analysis,” BMJ Open 5, no. 9 (2015): 1-10, at 9, available at <http://doi.org/10.1136/bmjopen-2014-007449> (last visited May 4, 2018).

33.

M. D.

Slater

et al ., “Assessing Media Campaigns Linking Marijuana Non-Use with Autonomy and Aspirations: ‘Be Under Your Own Influence’ and ONDCP’s ‘Above the Influence,’” Prevention Science 12, no. 1 (2011): 12-22, at 19, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042048/> (last visited January 21, 2018).

34.

“State Without StigMA,”

Office of the Governor of Massachusetts, available at <http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/state-without-stigma/> (last visited January 21, 2018); J. Sheridan, “Opioid Stigma Campaign Could Improve Treatment Access,” WFYI, available at <https://www.wfyi.org/news/articles/opioid-stigma-campaign-could-improve-treatment-access> (last visited January 21, 2018); D. Coffey, “Raising Awareness Of The Opioid Addiction Epidemic With Stigma Slam,” Hartford Courant, July 19, 2017, available at <http://www.courant.com/community/woodstock/hc-pt-woodstock-dmhas-hosts-stigma-slam-0720-20170719-story.html> (last visited January 21, 2018).

35.

J.D.

Livingston

et al ., “The Effectiveness of Interventions for Reducing Stigma Related to Substance Use Disorders: A Systematic Review,” Addiction 107, no. 1 (2012): 39-50, at 47, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272222/> (last visited January 21, 2018).

36.

National Prescription Drug Take Back Day, Drug Enforcement Administration, available at <https://www.deadiversion.usdoj.gov/drug_disposal/takeback/> (last visited February 8, 2018).

37.

As determined by state-by-state online searches.

38.

Arkansas Take Back, available at <http://www.artakeback.org/> (last visited January 21, 2018).

39.

“Prescription Drug Drop Boxes,”

Office of the Ohio Attorney General, available at <http://www.ohioattorneygeneral.gov/Individuals-and-Families/Victims/Drug-Diversion/Prescription-Drug-Drop-Boxes> (last visited January 21, 2018).

40.

K.L.

Egan

, “From Dispensed to Disposed: Evaluating the Effectiveness of Disposal Programs Through a Comparison with Prescription Drug Monitoring Program Data,” American Journal of Drug and Alcohol Abuse 43, no. 1 (2017): 69-77, at 74, available at <https://www.ncbi.nlm.nih.gov/pubmed/27797283> (last visited January 21, 2018).

41.

H.S.

Connery

, “Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions,” Harvard Review of Psychiatry 23, no. 2 (2015): 63-75, available at <https://www.ncbi.nlm.nih.gov/pubmed/25747920> (last visited January 21, 2018).

42.

Young and

Zur , “Medicaid and the Opioid Epidemic: Enrollment, Spending, and the Implications of Proposed Policy Changes,” Kaiser Family Foundation, available at <https://www.kff.org/medicaid/issue-brief/medicaid-andthe-opioid-epidemic-enrollment-spending-and-the-implications-of-proposed-policy-changes/> (last visited January 21, 2018).

43.

Bart

, “Maintenance Medication for Opiate Addiction: The Foundation of Recovery,” Journal of Addictive Diseases 31, no. 3 (2012): 207-225, at 217, available at <https://doi.org/10.1080/10550887.2012.694598> (last visited May 27, 2018).

44.

Boozang

et al ., “Coverage and Delivery of Adult Substance Abuse Services in Medicaid Managed Care,” Centers for Medicare & Medicaid Services, available at https://www.medicaid.gov/medicaid/benefits/downloads/cms-adult-substance-abuse-services-coverage.pdf (last visited February 9, 2018).

45.

C. M.

Grogan

et al ., “Survey Highlights Differences in Medicaid Coverage for Substance Use Treatment and Opioid use Disorder Medications,” Health Affairs (Millwood) 35, no. 12 (2016): 2289-2296, at 2292.

46.

Vestal

, “In Opioid Epidemic, Prejudice Persists Against Methadone,” Pew Trusts, available at <http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/11/11/inopioid-epidemic-prejudice-persists-against-methadone> (last visited January 22, 2018).

47.

Saloner

et al ., “Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment,” Psychiatric Services 67, no. 6 (2016): 676-679, 678, available at <https://ps.psychiatryonline.org/doi/full/10.1176/appi.ps.201500228> (last visited January 22, 2018).

48.

Kampman and

Jarvis , “American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use,” Journal of Addiction Medicine 9, no. 5 (2015): 358-367, at 361. B. Mund and K. Stith, “Buprenorphine MAT as an Imperfect Fix,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 279-291.

49.

“National Survey of Substance Abuse Treatment Services (N-SSATS): 2016,”

Substance Abuse and Mental Health Services Administration, available at <https://www.samhsa.gov/data/sites/default/files/2016_NSSATS.pdf> (last visited February 22, 2018).

50.

R.P.

Mattick

et al ., “Methadone Maintenance Therapy Versus No Opioid Replacement Therapy for Opioid Dependence,” Cochrane Database of Systematic Reviews 3 (2009): 1-25, available at http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD002209.pub2/abstract (last visited May 7, 2018).

51.

Kakko

et al ., “1-Year Retention and Social Function after Buprenorphine-Assisted Relapse Prevention Treatment for Heroin Dependence in Sweden,” Lancet 361, no. 9358 (2003): 662-668, at 662, available at <https://www.ncbi.nlm.nih.gov/pubmed/12606177> (last visited May 7, 2018).

52.

D.M.

Janowicz

, “HIV Transmission and Injection Drug Use: Lessons from the Indiana Outbreak,” Topics in Antiviral Medicine 24, no. 2 (2016): 90-92, at 90, available at <https://www.ncbi.nlm.nih.gov/pubmed/27841978> (last visited January 22, 2018).

53.

Bluthenthal

et al ., “Recommended Best Practices for Effective Syringe Exchange Programs in the United States: Results of a Consensus Meeting” (August 3, 2009), available at <http://harmreduction.org/wp-content/uploads/2012/01/NYC-SAP-Consensus-Statement.pdf> (last visited January 22, 2018).

54.

North American Syringe Exchange Network, NASEN, available at <https://nasen.org/directory/> (last visited January 22, 2018).

55.

Burris

, “Syringe Distribution Laws,” The Policy Surveillance Program, available at <http://lawatlas.org/datasets/syringe-policies-laws-regulating-non-retail-distribution-of-drug-parapherna> (last visited January 22, 2018).

56.

Harper

, “Indiana’s HIV Outbreak Leads to Reversal on Needle Exchanges,” NPR, available at <https://www.npr.org/sections/health-shots/2015/06/02/411231157/indianas-hiv-outbreak-leads-to-reversal-on-needle-exchanges> (last visited January 22, 2018).

57.

NASEN, supra note 54.

58.

CDC, “Syringe Services Program,” available at <https://www.cdc.gov/hiv/risk/ssps.html> (last visited January 22, 2018).

59.

CDC, “Access to Clean Syringes,” available at https://www.cdc.gov/policy/hst/hi5/cleansyringes/index.html (last visited January 22, 2018).

60.

Hedger

, “2nd Indiana County Ends Needle Exchange, with 1 Official Citing Moral Concerns,” IndyStar, October 23, 2017, available at <https://www.indystar.com/story/news/2017/10/23/2nd-indiana-county-ends-needle-exchange-one-official-citing-moral-concerns/787740001/> (last visited January 22, 2018).

61.

Drug Policy Alliance, “911 Good Samaritan Laws: Preventing Overdose Deaths, Saving Lives,” Drug Policy Alliance, available at <http://www.drugpolicy.org/sites/default/files/DPA_Fact%20Sheet_911%20Good%20Samaritan%20Laws_%28Feb.%202016%29.pdf> (last visited January 22, 2018).

62.

National Institute on Drug Abuse, “Opioid Overdose Reversal with Naloxone (Narcan, Evzio), National Institute on Drug Abuse, available at <http://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxone-narcan-evzio> (last visited January 22, 2018).

63.

National Conference of State Legislatures, “Drug Overdose Immunity and Good Samaritan Laws,” National Conference of State Legislatures, available at <http://www.ncsl.org/research/civil-and-criminal-justice/drug-overdose-immunity-good-samaritan-laws.aspx> (last visited January 22, 2018).

64.

N.M. Stat. § 24-23-2.

65.

Legal Science, “Naloxone Overdose Prevention Laws,” Prescription Drug Abuse Policy System, available at <http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139> (last visited January 22, 2018).

66.

Id .

67.

Id .

68.

Skwarecki

, “Narcan Is Now Available Over the Counter in 46 States,” LifeHacker, available at <http://vitals.life-hacker.com/narcan-is-now-available-over-the-counter-in-45-states-1819896107> (last visited January 22, 2018).

69.

K. J.

Morton

et al ., “Pharmacy-Based Statewide Naloxone Distribution: A Novel ‘Top-Down, Bottom-Up’ Approach,” 57, no. 2S (2017): S99-S106, at S100, available at <https://www.ncbi.nlm.nih.gov/pubmed/28292508> (last visited January 22, 2018).

70.

NBER, “With A Little Help from My Friends: The Effects of Naloxone Access and Good Samaritan Laws on Opioid-Related Deaths,” Working Paper No. 23171, at 2, available at <http://www.nber.org/papers/w23171.pdf> (last visited January 22, 2018).

71.

C. S.

Davis and

Carr , “Legal Changes to Increase Access to Naloxone for Opioid Overdose Reversal in the United States,” Drug and Alcohol Dependence 157 (2015): 112-120, available at <https://www.ncbi.nlm.nih.gov/pubmed/26507172> (last visited Jan. 22, 2018).

72.

Wheeler

et al ., “Opioid Overdose Prevention Programs Providing Naloxone to Laypersons – United States, 2014,” Morbidity and Mortality Weekly Report 64, no. 23 (2015): 631-635, available at <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6423a2.htm?s_cid=mm6423a2_w> (last visited January 22, 2018).

73.

P.J.

Davidson

et al ., “Witnessing Heroin-Related Overdoses: The Experiences of Young Injectors in San Francisco,” Addiction 97, no. 12 (2002): 1511-1516, available at <https://www.ncbi.nlm.nih.gov/pubmed/12472634> (last visited January 22, 2018).

74.

“911 Good Samaritan Laws: Preventing Overdose Deaths, Saving Lives,”

Drug Policy Alliance, available at <http://www.drugpolicy.org/sites/default/files/DPA_Fact%20Sheet_911%20Good%20Samaritan%20Laws_%28Feb.%202016%29.pdf> (last visited January 22, 2018).

75.

“Drug Overdose Immunity and Good Samaritan Laws,”

National Conference of State Legislatures, available at <www.ncsl.org/research/civil-and-criminal-justice/drug-overdose-immunity-good-samaritan-laws.aspx> (last visited February 24, 2018).

76.

C.J.

Banta-Green

et al ., “Washington’s 911 Good Samaritan Drug Overdose Law – Initial Evaluation Results,” Alcohol & Drug Abuse Institute University of Washington, available at <http://adai.uw.edu/pubs/infobriefs/adai-ib-2011-05.pdf> (last visited Jan. 22, 2018).

77.

Id .

78.

NBER, supra note 70.

79.

Lopez

, “The New War on Drugs,” Vox Media, available at <http://www.vox.com/policy-and-politics/2017/9/5/16135848/drug-war-opioid-epidemic> (last visited January 22, 2018).

80.

Id .

81.

Id .

82.

La. Stat. Ann. § 40:966(B)(1) & (4) (2017), amended by La. S.B. 87 (2014), available at <http://www.legis.la.gov/legis/BillInfo.aspx?i=223926> (last visited January 22, 2018).

83.

Indiana Code § 35-50-2-2.2 (2017), amended by Ind. H.B. 1235 (2016), available at <https://iga.in.gov/legislative/2016/bills/house/1235> (last visited Jan. 22, 2018).

84.

Id .

85.

Kansas H.B. 2044 (2013), amending Kan. Stat. Ann. § 21-5705 (2017).

86.

Drug Policy Alliance, “Drug-Induced Homicide Laws: A Misguided Response to Overdose Deaths,” Drug Policy Alliance, available at <http://www.drugpolicy.org/sites/default/files/Drug%20Policy%20Alliance_Fact%20Sheet_Drug-Induced%20Homicide.pdf> (last visited January 22, 2018).

87.

J. H.

Knight

, “The First Hit’s Free… Or Is It? Criminal Liability for Drug-Induced Death in New Jersey,” Seton Hall Law Review 34, no. 4 (2004): 1327-1352, at 1332, available at <https://law.shu.edu/Students/academics/journals/law-review/Issues/archives/upload/Knight.pdf> (last visited January 22, 2018).

88.

Drug Policy Alliance, supra note 61

89.

C. J.

Mumola and

J. C.

Karberg , “Drug Use and Dependence, State and Federal Prisoners, 2004,” U.S. Department of Justice, available at <http://www.bjs.gov/content/pub/pdf/dudsfp04.pdf> (last visited January 22, 2018).

90.

Lopez, supra note 79.

91.

R. K.

Pryzbylski

, “Correctional and Sentencing Reform for Drug Offenders: Research Findings on Selected Key Issues,” RKC Group, available at <http://www.ccjrc.org/wp-content/uploads/2016/02/Correctional_and_Sentencing_Reform_for_Drug_Offenders.pdf> (last visited January 22, 2018).

92.

H. A.

Pollack and

Reuter , “Does Tougher Enforcement Make Drugs More Expensive,” Addiction 109, no. 12, available at <http://faculty.publicpolicy.umd.edu/sites/default/files/reuter/files/pollack_and_reuter.pdf> (last visited January 22, 2018).

93.

“Drug Sentencing Trends,”

National Conference of State Legislatures, available at <http://www.ncsl.org/research/civil-and-criminal-justice/drug-sentencing-trends.aspx> (last visited January 22, 2018).

94.

Widgery

, “Pretrial Diversion,” National Conference of State Legislatures, available at <www.ncsl.org/research/civil-and-criminal-justice/pretrial-diversion.aspx> (last visited January 22, 2018).

95.

“Pretrial Diversion,”

National Conference of State Legislatures, available at <http://www.ncsl.org/research/civil-and-criminal-justice/pretrial-diversion.aspx> (last visited January 22, 2018).

96.

Davies

, “Expanding Drug Courts Won’t Help Ease the Opioid Crisis,” STAT, available at <http://www.statnews.com/2017/11/01/drug-courts-opioid-crisis/> (last visited January 22, 2018).

97.

“Neither Justice Nor Treatment: Drug Courts in the United States,”

Physicians for Human Rights, available at <http://physiciansforhumanrights.org/assets/misc/phr_drugcourts_report_singlepages.pdf> (last visited January 22, 2018).

98.

Mitchell

et al ., “Assessing the Effectiveness of Drug Courts on Recidivism: A Meta-Analytic Review of Traditional and Non-Traditional Drug Courts,” Journal of Criminal Justice 40, no. 1 (2012): 60-71, at 69, available at <http://courtinnovation.org/sites/default/files/documents/Assessing_Efectiveness.pdf> (last visited January 22, 2018); H. Matusow et al., “Medication Assisted Treatment in US Drug Courts: Results from a Nationwide Survey of Availability, Barriers and Attitudes,” Journal of Substance Abuse Treatment 44, no. 5 (2012): 473-480, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602216> (last visited May 7, 2018); “Neither Justice nor Treatment: Drug Courts in the United States,” Physicians for Human Rights (June 2017), available at <http://physiciansforhumanrights.org/assets/misc/phr_drugcourts_report_singlepages.pdf> (last visited May 7, 2018).

99.

A. R.

Gluck ,

Hall , and

Curfman , “Civil Litigation and the Opioid Epidemic: The Role of Courts in a National Health Crisis,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 351-366.

100.

Meier

, “In Guilty Plea, OxyContin Maker to Pay $600 Million,” New York Times, May 10, 2007, available at <http://www.nytimes.com/2007/05/10/business/11drug-web.html> (last visited January 22, 2018); John L. Brownlee & Heidi Coy, News Release, United States Attorney’s Office: The Purdue Frederick Company, Inc. and Top Executives Plead Guilty to Misbranding Oxycontin; Will Pay Over $600 Million (May 10, 2007).

101.

Id .

102.

Quinn

, “The Opioid Files: More Than 100 States and Cities Are Suing Drug Companies,” Governing, November 13, 2017, available at <www.governing.com/topics/health-human-services/gov-opioid-lawsuits-companies-states-cities.html> (last visited February 22, 2018).

103.

Noguchi

, “41 States to Investigate Pharmaceutical Companies over Opioids,” NPR, available at <https://www.npr.org/sections/thetwo-way/2017/09/19/552135830/41-states-to-investigate-pharmaceutical-companies-over-opioids> (last visited February 24, 2018).

104.

Raymond

, “U.S. Judge Schedules 2019 Trial in Opioid Litigation,” Reuters, April 11, 2018, available at <https://www.reuters.com/article/us-usa-opioids-litigation/u-s-judge-schedules-2019-trial-in-opioid-litigation-idUSKBN1HI3EI> (last visited May 27, 2018).

105.

Krans

, “More ‘Pill Mill’ Doctors Prosecuted Amidst Opioid Epidemic,” HealthLine, available at <http://www.healthline.com/health-news/pill-mill-doctors-prosecuted-amid-opioid-epidemic#1> (last visited January 22, 2018); M. Nedelman, “Doctors Increasingly Face Charges for Patient Overdoses,” CNN, available at <http://www.cnn.com/2017/07/31/health/opioid-doctors-responsible-overdose/index.html> (last visited January 22, 2018).

106.

Y. T.

Yang

et al ., “Managing Increasing Liability Risks Related to Opioid Prescribing,” American Journal of Medicine 130, no. 3 (2017): 249-250, available at <https://www.ncbi.nlm.nih.gov/pubmed/27644150> (last visited January 22, 2018).

107.

“Doctors and the Opioid Crisis: An AJC National Investigation,”

Atlanta Journal-Constitution, available at <https://www.ajc.com/news/public-affairs/doctors-and-the-opioid-crisis-ajc-national-investigation/qH23FJOrPnqSQzO9h-6seuJ/> (last visited February 23, 2018); M. Layton, “N.J. Disciplined Record Number of Doctors in Opioid Fight,” available at <https://www.northjersey.com/story/news/health/2017/03/01/nj-disciplined-record-number-doctors-drug-fight/98590064> (last visited February 23, 2018).

108.

Keilman

, “Chronic Pain Patients Say Opioid Crackdown is Hurting Them,” The Chicago Tribune, available at <www.chicagotribune.com/lifestyles/health/ct-opioid-patients-backlash-met-20170603-story.html> (last visited February 23, 2018).

109.

Blau

, “‘This is Just the Beginning’: Scope of Opioid Lawsuits Widens to Include Hospital Accreditor,” STAT, available at <http://www.statnews.com/2017/11/07/opioid-lawsuit-hospital-accreditor/> (last visited January 22, 2018); J. R. Schottenfeld, S. Waldman, A.R. Gluck, and D. G. Tobin, “Pain and Addiction in Specialty and Primary Care: The Bookends of a Crisis,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 220-237.

110.

“OxyContin Maker Stops Promoting Opioids, Cuts Sales Staff,”

Reuters, available at <https://www.reuters.com/article/us-usa-opioids-purduepharma/oxycontin-maker-stops-promoting-opioids-cuts-sales-staff-idUSKBN1FU0YL> (last visited Feb. 22, 2018).

111.

See Gluck, supra note 99.

112.

Dube

, “How States Engage in Evidence-Based Policymaking,” The Pew Charitable Trusts, available at <www.pewtrusts.org/en/research-and-analysis/reports/2017/01/how-states-engage-in-evidence-based-policymaking> (last visited January 24, 2018).

113.

Gourlay

, “Prisons to Expand Opioid Addiction Treatment,” Rhode Island Public Radio, available at <http://ripr.org/post/prisons-expand-opioid-addiction-treatment> (last visited January 22, 2018).

114.

“State of Illinois Opioid Action Plan,”

Illinois Department of Public Health, available at <http://dph.illinois.gov/sites/default/files/publications/Illinois-Opioid-Action-Plan-Sept-6-2017-FINAL.pdf> (last visited May 27, 2018).

115.

“State Unveils Comprehensive Plan for Addressing Opioid Epidemic,”

Dewitt Daily News, available at http://dewittdailynews.com/local-news/321959 (last visited January 22, 2018).

116.

Montanaro

et al ., “Rhode Island’s Strategic Plan on Addiction and Overdose: Four Strategies to Alter the Course of an Epidemic,” (November 4, 2015), available at <http://www.health.ri.gov/news/temp/RhodeIslandsStrategicPlanOnAddictionAndOverdose.pdf> (last visited January 22, 2018).

117.

“Proposed Opioid Response Plan for the State of West Virginia,”

West Virginia Department of Health and Human Resources, available at <https://dhhr.wv.gov/bph/Documents/ODCP%20Reports%202017/Proposed%20Opioid%20Response%20Plan%20for%20the%20State%20of%20West%20Virginia%201%2010%2018.pdf> (last visited February 10, 2018)

118.

“The Connecticut Opioid REsponse Initiative,”

Connecticut Department of Mental Health and Addiction Services, available at <http://www.ct.gov/dmhas/lib/dmhas/publications/core_initiative10.6.16.pdf> (last visited May 27, 2018).

119.

Montanaro

et al ., “Rhode Island’s Strategic Plan on Addiction and Overdose: Four Strategies to Alter the Course of an Epidemic,” (Nov. 4, 2015), available at <http://www.health.ri.gov/news/temp/RhodeIslandsStrategicPlanOnAddiction-AndOverdose.pdf> (last visited January 22, 2018).

120.

Substance Abuse and Mental Health Services Administration, “SAMHSA to Award Nearly $1 Billion in New Grants to Address the Nation’s Opioid Crisis,” (December 14, 2016) available at <https://www.samhsa.gov/newsroom/press-announcements/201612141015> (last visited February 10, 2018).

121.

Beck

, “WV DHHR Gets $5 Million Opioid Grant, but Says State Needs More,” Charleston Gazette-Mail, December 2, 2017, available at <https://www.wvgazettemail.com/news/health/wv-dhhr-gets-million-opioid-grant-but-says-state-needs/article_1d4581cd-fe6d-5121-be32-7dc3f07b96e1.html> (last visited February 10, 2018).

122.

Pittman

, “Massachusetts Receives Nearly $12 Million in Federal Funding to Fight Opioid Epidemic,” Commonwealth of Massachusetts, available at <https://www.mass.gov/news/massachusetts-receives-nearly-12-million-in-federal-funding-to-fight-opioid-epidemic> (last visited February 10, 2018).

123.

Hitchcock

, “The Opioid Crisis Is Real, But Not Yet A Threat To State Credit Quality,” S&P Global Market Intelligence, available at <https://www.capitaliq.com/CIQDotNet/CreditResearch/RenderArticle.aspx?articleId=1940072&SctArtId=441168&from=CM> (last visited January 22, 2018)

124.

Povich

, “In Tide of Red Ink, Some States Show Surpluses,” The Pew Charitable Trusts, available at <http://www.pewtrusts.org/en/research-and-analysis/blogs/state-line/2017/01/24/in-tide-of-red-ink-some-states-show-surpluses> (last visited January 22, 2018).

125.

See Hall, supra note 99.

126.

Finklea

et al ., “Prescription Drug Monitoring Programs,” Congressional Research Service (Mar. 24, 2014), available at <https://fas.org/sgp/crs/misc/R42593.pdf> (last visited January 21, 2018).

127.

Orozco

, “New Statewide Campaign Launched to Fight Opioid Crisis in Ohio,” WSYX, available at <http://abc6onyour-side.com/news/local/new-statewide-campaign-launched-tofight-opioid-crisis-in-ohio> (last visited Jan. 22, 2018).

128.

Sofield

, “Public Safety Departments Get More Funds Due To Prison Overcrowding, Opioid Crisis,” Levittown Now, available at <http://levittownnow.com/2017/09/07/public-safety-departments-get-funds-due-prison-overcrowding-opioid-crisis> (last visited January 22, 2018); T. Sears, “Henrico Jail’s Rising Women Population Leaves People Sleeping on Floor,” WTVR, available at <http://wtvr.com/2017/10/09/henrico-jails-rising-women-population-leaves-people-sleeping-on-floor> (last visited January 22, 2018).

129.

“Is Drug Addiction Treatment Worth its Cost?,”

National Institute on Drug Abuse, available at <https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/frequently-asked-questions/drug-addiction-treatment-worth-its-cost> (last visited February 10, 2018)

130.

Jones

et al ., “National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment,” American Journal of Public Health 105, no. 8 (2015): 55-63, at 56.

131.

Murphy

et al ., “Show Me the Money: Economic Evaluations of Opioid Use Disorder Interventions,” Leonard Davis Institute of Health Economics, available at <https://ldi.upenn.edu/brief/show-me-money-economic-evaluations-opioid-use-disorder-interventions> (last visited February 11, 2018).

132.

Baser

et al ., “Cost and Utilization Outcomes of Opioid-Dependence Treatments,” The American Journal of Managed Care 17, Supplement 8 (2011): S235-S248, available at <www.ajmc.com/journals/supplement/2011/a369_june11/a369_11jun_alcohol_s235to48> (last visited February 11, 2018).

State Responses to the Opioid Crisis

Abstract

Get full access to this article

References